Drug Profile
CRE 16336
Alternative Names: EML 16336Latest Information Update: 11 Jun 2003
Price :
$50
*
At a glance
- Originator Merck KGaA; Ono Pharmaceutical
- Developer Merck KGaA
- Class
- Mechanism of Action Glucose stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Insulin resistance; Type 2 diabetes mellitus
Most Recent Events
- 11 Jun 2003 Discontinued - Phase-II for Insulin resistance in Europe (unspecified route)
- 11 Jun 2003 Discontinued - Phase-II for Type-2 diabetes mellitus in Europe (PO)
- 21 May 2003 Suspended - Phase-II for Insulin resistance in Europe (unspecified route)